Logo

Polpharma & Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar- ranibizumab)

Share this

Polpharma & Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar- ranibizumab)

Shots:

  • Polpharma has reported that its JV company- Bioeq has submitted a BLA for FYB201 (biosimilar referencing Lucentis) to the FDA. FYB201 was originally licensed from Formycon AG
  • The launch of biosimilar ranibizumab may increase market competition- reduce cost and expand patient access with proven analytical & clinical similarity to Lucentis
  • Lucentis is a mAb fragment used to treat various types of macular-degenerative diseases including wet AMD- DR- macular edemas and MCNV. If approved- Coherus will commercialize FYB201 in the US

  | Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions